Elanco Animal Health Inc (ELAN) concluded trading on Thursday at a closing price of $14.69, with 6.5 million shares of worth about $95.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 21.40% during that period and on July 24, 2025 the price saw a loss of about -2.20%. Currently the company’s common shares owned by public are about 496.46M shares, out of which, 491.95M shares are available for trading.
Stock saw a price change of -1.80% in past 5 days and over the past one month there was a price change of 8.73%. Year-to-date (YTD), ELAN shares are showing a performance of 14.77% which increased to 21.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.02 but also hit the highest price of $15.78 during that period. The average intraday trading volume for Elanco Animal Health Inc shares is 5.68 million. The stock is currently trading 0.04% above its 20-day simple moving average (SMA20), while that difference is up 5.48% for SMA50 and it goes to 20.01% higher than SMA200.
Elanco Animal Health Inc (NYSE: ELAN) currently have 496.46M outstanding shares and institutions hold larger chunk of about 100.35% of that.
The stock has a current market capitalization of $7.30B and its 3Y-monthly beta is at 1.67. PE ratio of stock for trailing 12 months is 19.60, while it has posted earnings per share of $0.75 in the same period. Its PEG reads 3.07 and has Quick Ratio of 1.46 while making debt-to-equity ratio of 0.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELAN, volatility over the week remained 2.31% while standing at 2.54% over the month.
Stock’s fiscal year EPS is expected to drop by -7.38% while it is estimated to increase by 13.14% in next year. EPS is likely to shrink at an annualized rate of 6.39% for next 5-years, compared to annual growth of 29.95% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on July 17, 2025 offering an Outperform rating for the stock and assigned a target price of $18 to it. On December 09, 2024, UBS Initiated their recommendations, while on December 02, 2024, Leerink Partners Initiated their ratings for the stock with a price target of $14. Stock get an Equal-weight rating from Morgan Stanley on September 19, 2024.
